Oxygen Biotherapeutics, Inc., formerly known as Synthetic Blood International, Inc., is dedicated to transforming patient care by developing advanced oxygen-based therapies using Oxycyte®, the company’s perfluorocarbon (PFC) therapeutic oxygen carrier, and other solutions. The company believes Oxycyte has the potential for use in multiple indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. The company estimates that the combined annual incidence for these indications in the United States and Europe is more than 12 million.